Ovid trims costs, gets Marinus cash but warns of funding shortfall and Nasdaq delist risk

Ovid Therapeutics Inc. (NASDAQ: OVID) - Quick internal read

What's happening inside: management is shrinking costs and pausing at least one program while pursuing strategic alternatives to extend runway. A one‑time Marinus payment boosted Q2 revenue; prior period's large "other income" was a one-off Ligand valuation adjustment in 2024. Company still has substantial doubt about continued operations without new financing and has Nasdaq bid‑price pressure (board authorized a possible reverse split).

Key points & statistics (as reported)
* Cash, cash equivalents and marketable securities (June 30, 2025): $38.3M (cash & equivalents $30.346M; marketable securities $9.932M).
* Total assets: $77,428k; total liabilities: $21,639k; stockholders' equity: $55,789k.
* Working capital: $33.2M. Accumulated deficit: $319.218M.
* Common shares outstanding: 71,109,514; Series A preferred outstanding: 1,250 (convertible into 1,250,000 common shares).
* Revenue - Q2 2025 license & other: $6.272M (Q2 2024: $0.169M). Six months 2025: $6.402M vs $0.317M in 2024 (primarily Marinus amendment/one‑time receipts).
* R&D expense - Q2 2025: $6.465M (Q2 2024: $12.582M). Six months: $13.123M vs $22.984M (drop driven by pause of OV888 and headcount reductions).
* G&A expense - Q2 2025: $4.880M (Q2 2024: $8.104M). Six months: $10.902M vs $15.267M.
* Total operating expenses - Q2 2025: $11.345M (Q2 2024: $20.686M). Six months: $24.025M vs $38.251M.
* Loss from operations - Q2 2025: $(5.073)M (Q2 2024: $(20.517)M). Six months: $(17.623)M vs $(37.934)M.
* Other income (expense), net - Q2 2025: $0.389M vs $29.038M in Q2 2024 (2024 included $29M adjustment on Ligand royalty monetization). Six months: $2.704M vs $34.760M.
* Net (loss) income - Q2 2025: $(4.684)M (Q2 2024: +$8.521M). Six months: $(14.919)M vs $(3.174)M.
* Cash used in operations (six months): $(15.054)M; cash provided by investing (maturities of securities): $17.155M; net increase in cash: $2.114M.
* Long‑term equity investments (Gensaic + Graviton + Marinus proceeds): $20.908M.
* Lease remaining commitments: $18.136M (10‑year HQ lease; $2.3M/yr base rent).
* Stock‑based compensation (six months): $2.503M; unrecognized stock‑based comp: $11.2M.

Positive aspects of the income statement and balance sheet
* Revenue spike in Q2 from the Marinus amendment - $6.3M recognized; this materially reduced near‑term cash burn pressure.
* Operating expense discipline - R&D and G&A both fell materially YoY (R&D down ~$9.9M six months; G&A down ~$4.4M) after program pauses and 2024 restructuring.
* Cash + marketable securities of $38.3M provide immediate liquidity and maturities that management can access (they matured securities to provide cash in H1).
* Recovery of $1.8M fraudulent transfer (recorded in Jan 2025) removed that non‑operating loss from balance sheet.
* Long‑term equity stakes (Graviton/Gensaic) provide non‑cash upside potential (carrying value ~$20.9M).

Negative aspects / risks shown by the income statement and disclosures
* Company remains unprofitable: six‑month net loss $(14.919)M and accumulated deficit $319.2M.
* Other income in 2024 included a one‑time $29M Ligand valuation adjustment - not recurring; H1 2025 other income is much smaller, so earnings volatility is high and prior profit was not operational.
* Working capital ($33.2M) and current runway are limited - management states current cash/securities will not be sufficient to fund plans through the next 12 months and substantial doubt about going concern exists.
* Marketable securities declined from $26.8M at year end to $9.932M - liquidity mix shifted; reliance on maturing securities to plug shortfalls is a timing risk.
* High fixed commitments remain (lease obligations ~$18.1M) and potential milestone payments under license agreements total up to ~$279.3M (contingent but material if triggered).
* Nasdaq bid‑price noncompliance: received deficiency notice, transferred to Nasdaq Capital Market and given until Feb 9, 2026 to regain $1.00 bid; board authorized 1:10-1:40 reverse split if needed (shareholders approved). Reverse split would reduce float and may be dilutive in perception.
* Programs risk: OV888 (GV101) program is paused - reduces near‑term R&D spend but also reduces pipeline momentum and optionality.
* Dependence on one‑time licensing cash and external financing - company must execute strategic alternatives (equity, partnerships, asset sales) or dilute shareholders.

Operational / strategic highlights
* Pipeline: KCC2 library (OV350), OV888 (GV101) paused, OV329 ongoing; two programs in clinical trials, third expected to start Q2 2026 (company statement).
* Marinus amendment: one‑time $7.0M payment received in June 2025 - $6.3M recognized as revenue, $0.7M deferred until license transfer; meaningful near‑term cash inflow.
* Takeda/RLT legacy: soticlestat program discontinued by Takeda (Jan 2025); prior Ligand monetization produced a large 2024 accounting gain that is not repeatable.
* Management is evaluating strategic alternatives (additional financings, partnerships, asset sales or rights relinquishment) and may need to cede program rights to extend runway.
* Nasdaq: additional 180‑day cure period to regain $1.00 bid (to Feb 9, 2026); reverse split option approved by shareholders (1:10-1:40) to try to regain compliance.

Straightforward takeaways
* Ovid (NASDAQ: OVID) has cut costs and recognized a one‑time license payment that improved H1 results, but core operations still burn cash and produced a $14.9M loss in the first six months of 2025.
* The company has ~$38.3M of cash + securities today but says that is not enough to fund its stated plans for 12 months - management must secure financing or strategic transactions soon, which will likely dilute shareholders or require licensing away assets.
* Balance sheet holds useful long‑term equity stakes (~$20.9M) and some one‑time upside was realized in prior periods; however, recurring revenue is minimal and results are driven by licensing events and one‑offs rather than product sales.
* Near‑term stock catalysts: successful strategic financing/partnering, execution of reverse split (if needed) to maintain Nasdaq listing, progress or re‑start of paused programs, or additional licensing milestone payments.
* Risks remain high: going‑concern language, delisting risk if market bid stays under $1, R&D program uncertainty and potential dilution from financings or Series A conversions.

If you want, I can prepare a one‑page investor‑style dashboard (P&L bridge, runway sensitivity to burn, and potential dilution scenarios) using these numbers.